<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02149914</url>
  </required_header>
  <id_info>
    <org_study_id>REC103-20</org_study_id>
    <nct_id>NCT02149914</nct_id>
  </id_info>
  <brief_title>The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients</brief_title>
  <official_title>The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Tzu Chi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Tzu Chi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastroesophageal reflux disease(GERD) mainly related to the reflux of stomach content induced&#xD;
      by the dysfunction of lower esophageal sphincter. Proton pump inhibitors (PPI) can&#xD;
      effectively block gastric acid secretion but the drug reactions and the degree of improvement&#xD;
      in symptoms are sometimes unpredictable. The aim of this study is to investigate the&#xD;
      association between the clinical efficacy of PPI in patients with GERD and the personal&#xD;
      physical status by Ryodoraku and ANSWatch.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroesophageal reflux disease(GERD) is a common disease, mainly related to the reflux of&#xD;
      stomach content induced by the dysfunction of lower esophageal sphincter. The common symptoms&#xD;
      of GERD are heartburn, acid regurgitation, chest pain and globus hystericus. The methods to&#xD;
      treat GERD are changes of lifestyle, pharmacotherapy, antireflux surgery and endoscopy.&#xD;
      Proton pump inhibitors (PPI) can effectively block gastric acid secretion and promote the&#xD;
      repair of esophagus, but the drug reactions and the degree of improvement in symptoms are&#xD;
      sometimes unpredictable. Recently there are many instruments used to analyze personal&#xD;
      physical status. Meridian energy analysis device ( Ryodoraku ) is used to assess the energy&#xD;
      of meridian system by analysis of resistance of the skin surface, as well as the wrist-worn&#xD;
      heart rate monitor (ANSWatch) used to assess the autonomic nervous system by analysis of&#xD;
      heart rate variability. Therefore, the aim of this study is to investigate the association&#xD;
      between the clinical efficacy of PPI in patients with GERD and the personal physical status&#xD;
      by Ryodoraku and ANSWatch.&#xD;
&#xD;
      Investigators will recruit 120 patients with GERD in clinic who have to receive PPIs for four&#xD;
      weeks and assess each volunteer before and after taking the medication. Assessment methods :&#xD;
      1. ANSWatch to assess the autonomic nervous system, 2. Ryodoraku to assess the energy of&#xD;
      meridian system, 3. Upper gastrointestinal endoscopy to assess the grade of reflux&#xD;
      esophagitis, 4. gastroesophageal reflux disease questionnaire to assess the severity of GERD.&#xD;
      Investigators analysed and compared the database from the assessments between before and&#xD;
      after taking the medication.&#xD;
&#xD;
      Investigators anticipate to substantiate that the changes of Ryodoraku and ANSWatch are good&#xD;
      predictors for the clinical efficacy of PPI in patients with GERD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>gastroesophageal reflux disease questionnaire</measure>
    <time_frame>four weeks</time_frame>
    <description>To assess the severity of GERD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Upper gastrointestinal endoscopy</measure>
    <time_frame>four weeks</time_frame>
    <description>To assess the grade of reflux esophagitis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-erosive Reflux Disease</condition>
  <condition>Barrett's Esophagus</condition>
  <arm_group>
    <arm_group_label>PPI treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with GERD would be assessed by ANSWatch. Ryodoraku, UGI endoscopy, and GerdQ before taking PPIs and after taking PPI 20mg tablet by mouth everyday for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ryodoraku</intervention_name>
    <description>Ryodoraku to assess the energy of meridian system for each patient before and after taking the medication</description>
    <arm_group_label>PPI treatment</arm_group_label>
    <other_name>Meridian energy analysis device</other_name>
    <other_name>M.E.A.D</other_name>
    <other_name>Skin Response Measurement Device</other_name>
    <other_name>Me-Professional</other_name>
    <other_name>Me-100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ANSWatch</intervention_name>
    <description>ANSWatch to assess the autonomic nervous system for each patient before and after taking the medication</description>
    <arm_group_label>PPI treatment</arm_group_label>
    <other_name>&quot;Taiwan Scientific&quot; Noninvasive Blood Pressure Meter</other_name>
    <other_name>Wrist-worn heart rate monitor</other_name>
    <other_name>TS-0411</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UGI endoscopy</intervention_name>
    <description>UGI endoscopy to assess the grade of reflux esophagitis for each patient before and after taking the medication</description>
    <arm_group_label>PPI treatment</arm_group_label>
    <other_name>Upper gastrointestinal endoscope</other_name>
    <other_name>Fujinon EG350N</other_name>
    <other_name>Fujinon EG590WR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GerdQ</intervention_name>
    <description>GerdQ to assess the severity of GERD for each patient before and after taking the medication</description>
    <arm_group_label>PPI treatment</arm_group_label>
    <other_name>Gastroesophageal reflux disease questionnaire</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPI</intervention_name>
    <arm_group_label>PPI treatment</arm_group_label>
    <other_name>Proton Pump Inhibitor</other_name>
    <other_name>Rabeprazole</other_name>
    <other_name>Pariet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female&#xD;
&#xD;
          -  age of 20-75 years&#xD;
&#xD;
          -  patients with GERD who have to receive PPIs for four weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suffering from peptic ulcer, gallstones, cancer, and Barrett's esophagus&#xD;
&#xD;
          -  previously underwent the esophagus, stomach or duodenum surgery&#xD;
&#xD;
          -  Lactating women or pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mei-Ling Shen, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Taichung Tzu Chi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taichung Tzu Chi Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>427</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>May 18, 2014</study_first_submitted>
  <study_first_submitted_qc>May 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <last_update_submitted>November 19, 2014</last_update_submitted>
  <last_update_submitted_qc>November 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taichung Tzu Chi Hospital</investigator_affiliation>
    <investigator_full_name>Mei-Ling Shen</investigator_full_name>
    <investigator_title>Mei-Ling Shen</investigator_title>
  </responsible_party>
  <keyword>Ryodoraku</keyword>
  <keyword>Meridian energy</keyword>
  <keyword>Heart rate variability</keyword>
  <keyword>Autonomic Nervous System</keyword>
  <keyword>GERD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

